Behçet Hastalığına Bağlı Üveitin Tedavisinde Biyolojik Ajanların Kullanımı

Tugal-Tutkun, Ilknur; ESER ÖZTÜRK, HİLAL

Behçet Hastalığına Bağlı Üveitin Tedavisinde Biyolojik Ajanların Kullanımı

Hilal ESER ÖZTÜRK, (Ondokuz Mayıs Üniversitesi, Göz Hastalıkları Anabilim Dalı, Samsun, Türkiye)

İlknur Tuğal TUTKUN (İstanbul Üniversitesi, İstanbul Tıp Fakültesi, Göz Hastalıkları Anabilim Dalı, İstanbul, Türkiye)

Güncel Retina Dergisi

27 0

Yıl: 2018 Cilt: 2 Sayı: 4 Sayfa Aralığı: 358 - 365 Metin Dili: Türkçe İndeks Tarihi: 24-05-2019

Behçet Hastalığına Bağlı Üveitin Tedavisinde Biyolojik Ajanların Kullanımı

Öz:

Behçet hastalığının göz tutulumu bilateral, tekrarlayan non-granülomatöz panüveit ve retinal vaskülit ile karakterizedirve ciddi retinal hasara ve görme kaybına yol açabilir. Behçet üveitinin yönetiminde arka segment tutulumu sistemikimmünmodülatuar tedavi için mutlak endikasyondur. Steroidler ve immunsüpresif ajanları içeren konvansiyonel tedavive interferonlar oküler inflamasyonu ve retinal hasarı önlemede her zaman yeterli olmayabilir. Ayrıca bu ilaçlara bağlıyan etkiler kullanımlarını kısıtlayabilir. Bu durumda göreceli olarak yeni kullanıma giren biyolojik ajanların geliştirilmesiBehçet üveitine bağlı görme kaybının önlenmesinde yeni ufuklar açmıştır. Bu ajanlar arasında tümör nekroz faktör alfa(TNF-α) inhibitörleri (infliksimab, adalimumab, golimumab, etanersept ve sertolizumab), IL-1 inhibitörleri (anakinra,kanakinumab, gevokizumab), IL-6 inhibitörleri (tosilizumab) ve B hücre inhibitörleri (anti-CD20 antikoru-rituksimab)sayılabilir. Bu derleme Behçet üveitinin tedavisinde biyolojik ajanların kullanımını gözden geçirmeyi amaçlamaktadır..

Anahtar Kelime:

Konular: Cerrahi

Biologics in Treatment of Behçet Uveitis

Öz:

Ocular involvement of Behçet disease is characterized by bilateral, recurrent non-granulomatous panuveitis and retinal vasculitis and may lead to serious retinal damage and loss of vision. Posterior segment involvement is an absolute indication for immunomudulatory therapy in management of Behçet uveitis. Conventional therapy including steroids and immunosuppressives and interferons may not be sufficient to prevent retinal damage. Besides, adverse reactions related to these agents may limit their usage. In this situation, relatively new biologic agents open new horizons for preventing visual loss related to Behçet uveitis. These agents include tumor necrosis factor alpha (TNF-α) inhibitors (infliximab, adalimumab, golimumab, etanercept ve certolizumab), IL-1 inhibitors (anakinra, canakinumab, gevokizumab), IL-6 inhibitors (tocilizumab) and B-cell inhibitors (rituximab). This review aims to provide an overview of biologics in the treatment of Behçet uveitis.

Anahtar Kelime:

Konular: Cerrahi

Belge Türü: Makale Makale Türü: Derleme Erişim Türü: Bibliyografik

Tugal-Tutkun I, Cingu K, Kir N, Yeniad B, Urgancioglu M, Gul A. Use of laser flare-cell photometry to quantify intraocular inflammation in patients with Behcet uveitis. Graefes Arch Clin Exp Ophthalmol. 2008;246(8):1169-1177.
Tugal-Tutkun I. Imaging in the diagnosis and management of Behcet disease. Int Ophthalmol Clin. 2012;52(4):183-190.
Zierhut M, Abu El-Asrar AM, Bodaghi B, Tugal-Tutkun I. Therapy of ocular Behcet disease. Ocul Immunol Inflamm. 2014;22(1):64-76.
Mesquida M, Molins B, Llorenc V, Sainz de la Maza M, Hernandez MV, Espinosa G, et al. Proinflammatory cytokines and C-reactive protein in uveitis associated with Behcet’s disease. Mediators Inflamm. 2014;2014:396204.
Hatemi G, Silman A, Bang D, Bodaghi B, Chamberlain AM, Gul A, et al. EULAR recommendations for the management of Behcet disease. Ann Rheum Dis. 2008;67(12):1656-1662.
Caso F, Costa L, Rigante D, Lucherini OM, Caso P, Bascherini V, et al. Biological treatments in Behcet’s disease: beyond anti-TNF therapy. Mediators Inflamm. 2014;2014:107421.
Mesquida M, Molins B, Llorenc V, Hernandez MV, Espinosa G, Dick AD, et al. Current and future treatments for Behcet’s uveitis: road to remission. International ophthalmology. 2014;34(2):365-381.
Hazirolan D, Stubiger N, Pleyer U. Light on the horizont: biologicals in Behcet uveitis. Acta Ophthalmol. 2013;91(4):297-306.
Ahn JK, Yu HG, Chung H, Park YG. Intraocular cytokine environment in active Behcet uveitis. Am J Ophthalmol. 2006;142(3):429-434.
Santos Lacomba M, Marcos Martin C, Gallardo Galera JM, Gomez Vidal MA, Collantes Estevez E, Ramirez Chamond R, et al. Aqueous humor and serum tumor necrosis factor-alpha in clinical uveitis. Ophthalmic Res. 2001;33(5):251-255.
Misumi M, Hagiwara E, Takeno M, Takeda Y, Inoue Y, Tsuji T, et al. Cytokine production profile in patients with Behcet’s disease treated with infliximab. Cytokine. 2003;24(5):210-218.
Sfikakis PP, Theodossiadis PG, Katsiari CG, Kaklamanis P, Markomichelakis NN. Effect of infliximab on sight-threatening panuveitis in Behcet’s disease. Lancet. 2001;358(9278):295-296.
Sfikakis PP, Kaklamanis PH, Elezoglou A, Katsilambros N, Theodossiadis PG, Papaefthimiou S, et al. Infliximab for recurrent, sight-threatening ocular inflammation in Adamantiades-Behcet disease. Ann Intern Med. 2004;140(5):404-406.
.Ohno S, Nakamura S, Hori S, Shimakawa M, Kawashima H, Mochizuki M, et al. Efficacy, safety, and pharmacokinetics of multiple administration of infliximab in Behcet’s disease with refractory uveoretinitis. J Rheumatol. 2004;31(7):1362-1368.
Tugal-Tutkun I, Mudun A, Urgancioglu M, Kamali S, Kasapoglu E, Inanc M, et al. Efficacy of infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine, and corticosteroids in Behcet’s disease: an open-label trial. Arthritis Rheum. 2005;52(8):2478-2484.
16.Yamada Y, Sugita S, Tanaka H, Kamoi K, Kawaguchi T, Mochizuki M. Comparison of infliximab versus ciclosporin during the initial 6-month treatment period in Behcet disease. Br J Ophthalmol. 2010;94(3):284-288.
Tabbara KF, Al-Hemidan AI. Infliximab effects compared to conventional therapy in the management of retinal vasculitis in Behcet disease. Am J Ophthalmol. 2008;146(6):845-850 e841.
Markomichelakis N, Delicha E, Masselos S, Fragiadaki K, Kaklamanis P, Sfikakis PP. A single infliximab infusion vs corticosteroids for acute panuveitis attacks in Behcet’s disease: a comparative 4-week study. Rheumatology (Oxford). 2011;50(3):593- 597.
Abu El-Asrar AM, Abboud EB, Aldibhi H, Al-Arfaj A. Long-term safety and efficacy of infliximab therapy in refractory uveitis due to Behcet’s disease. International ophthalmology. 2005;26(3):83-92.
Capella MJ, Foster CS. Long-term efficacy and safety of infliximab in the treatment of Behcet’s disease. Ocul Immunol Inflamm. 2012;20(3):198-202.
Niccoli L, Nannini C, Benucci M, Chindamo D, Cassara E, Salvarani C, et al. Long-term efficacy of infliximab in refractory posterior uveitis of Behcet’s disease: a 24-month follow-up study. Rheumatology (Oxford). 2007;46(7):1161-1164.
Accorinti M, Pirraglia MP, Paroli MP, Priori R, Conti F, Pivetti-Pezzi P. Infliximab treatment for ocular and extraocular manifestations of Behcet’s disease. Jpn J Ophthalmol. 2007;51(3):191-196.
Okada AA, Goto H, Ohno S, Mochizuki M, Ocular Behcet’s Disease Research Group Of J. Multicenter study of infliximab for refractory uveoretinitis in Behcet disease. Archives of ophthalmology. 2012;130(5):592-598.
Takeuchi M, Kezuka T, Sugita S, Keino H, Namba K, Kaburaki T, et al. Evaluation of the long-term efficacy and safety of infliximab treatment for uveitis in Behcet’s disease: a multicenter study. Ophthalmology. 2014;121(10):1877-1884.
Arida A, Fragiadaki K, Giavri E, Sfikakis PP. Anti-TNF agents for Behcet’s disease: analysis of published data on 369 patients. Semin Arthritis Rheum. 2011;41(1):61- 70.
Tugal-Tutkun IY, Ö; Gül, A. Konvansiyonel İmmunsupresif ve/veya İnterferon- Alfa Tedavisine Dirençli Behçet Üveiti Olgularında İnfliksimab Tedavisi. T Oft Gaz. 2008;38:485-493.
Adan A, Hernandez V, Ortiz S, Molina JJ, Pelegrin L, Espinosa G, et al. Effects of infliximab in the treatment of refractory posterior uveitis of Behcet’s disease after withdrawal of infusions. International ophthalmology. 2010;30(5):577-581.
Yamada Y, Sugita S, Tanaka H, Kamoi K, Takase H, Mochizuki M. Timing of recurrent uveitis in patients with Behcet’s disease receiving infliximab treatment. Br J Ophthalmol. 2011;95(2):205-208.
Calvo-Rio V, Blanco R, Beltran E, Sanchez-Burson J, Mesquida M, Adan A, et al. Anti-TNF-alpha therapy in patients with refractory uveitis due to Behcet’s disease: a 1-year follow-up study of 124 patients. Rheumatology (Oxford). 2014;53(12):2223- 2231.
Elezoglou A, Kafasi N, Kaklamanis PH, Theodossiadis PG, Kapsimali V, Choremi E, et al. Infliximab treatment-induced formation of autoantibodies is common in Behcet’s disease. Clin Exp Rheumatol. 2007;25(4 Suppl 45):S65-69.
Mushtaq B, Saeed T, Situnayake RD, Murray PI. Adalimumab for sight-threatening uveitis in Behcet’s disease. Eye (Lond). 2007;21(6):824-825.
Bawazeer A, Raffa LH, Nizamuddin SH. Clinical experience with adalimumab in the treatment of ocular Behcet disease. Ocul Immunol Inflamm. 2010;18(3):226-232.
.Leccese P, Latanza L, D’Angelo S, Padula A, Olivieri I. Efficacy of switching to adalimumab in a patient with refractory uveitis of Behcet’s disease to infliximab. Clin Exp Rheumatol. 2011;29(4 Suppl 67):S93.
Olivieri I, Leccese P, D’Angelo S, Padula A, Nigro A, Palazzi C, et al. Efficacy of adalimumab in patients with Behcet’s disease unsuccessfully treated with infliximab. Clin Exp Rheumatol. 2011;29(4 Suppl 67):S54-57.
Takase K, Ohno S, Ideguchi H, Uchio E, Takeno M, Ishigatsubo Y. Successful switching to adalimumab in an infliximab-allergic patient with severe Behcet disease- related uveitis. Rheumatol Int. 2011;31(2):243-245.
Fabiani C, Vitale A, Emmi G, Vannozzi L, Lopalco G, Guerriero S, et al. Efficacy and safety of adalimumab in Behcet’s disease-related uveitis: a multicenter retrospective observational study. Clin Rheumatol. 2017;36(1):183-189.
Mesquida M, Victoria Hernandez M, Llorenc V, Pelegrin L, Espinosa G, Dick AD, et al. Behcet disease-associated uveitis successfully treated with golimumab. Ocul Immunol Inflamm. 2013;21(2):160-162.
Fabiani C, Sota J, Rigante D, Vitale A, Emmi G, Vannozzi L, et al. Rapid and Sustained Efficacy of Golimumab in the Treatment of Multirefractory Uveitis Associated with Behcet’s Disease. Ocul Immunol Inflamm. 2017:1-6.
Curigliano V, Giovinale M, Fonnesu C, Cerquaglia C, Verrecchia E, Turco S, et al. Efficacy of etanercept in the treatment of a patient with Behcet’s disease. Clinical Rheumatology. 2008;27(7):933-936.
Cantarini L, Tinazzi I, Caramaschi P, Bellisai F, Brogna A, Galeazzi M. Safety and efficacy of etanercept in children with juvenile-onset Behcets disease. Int J Immunopathol Pharmacol. 2009;22(2):551-555.
Kakkassery V, Mergler S, Pleyer U. Anti-TNF-alpha Treatment: A Possible Pro moter in Endogenous Uveitis? Observational Report on Six Patients: Occurrence of Uveitis Following Etanercept Treatment. Curr Eye Res. 2010;35(8):751-756.
Galor A, Perez VL, Hammel JP, Lowder CY. Differential effectiveness of etanercept and infliximab in the treatment of ocular inflammation. Ophthalmology. 2006;113(12):2317-2323.
Levy-Clarke G, Jabs DA, Read RW, Rosenbaum JT, Vitale A, Van Gelder RN. Expert panel recommendations for the use of anti-tumor necrosis factor biologic agents in patients with ocular inflammatory disorders. Ophthalmology. 2014;121(3):785-796 e783.
Cordero-Coma M, Sobrin L. Anti-tumor necrosis factor-alpha therapy in uveitis. Surv Ophthalmol. 2015;60(6):575-589.
Rudwaleit M, Rosenbaum JT, Landewe R, Marzo-Ortega H, Sieper J, van der Heijde D, et al. Observed Incidence of Uveitis Following Certolizumab Pegol Treatment in Patients With Axial Spondyloarthritis. Arthritis Care Res (Hoboken). 2016;68(6):838-844.
Llorenc V, Mesquida M, Sainz de la Maza M, Blanco R, Calvo V, Maiz O, et al. Certolizumab Pegol, a New Anti-TNF-alpha in the Armamentarium against Ocular Inflammation. Ocul Immunol Inflamm. 2016;24(2):167-172.
Mahadevan U, Wolf DC, Dubinsky M, Cortot A, Lee SD, Siegel CA, et al. Placental transfer of anti-tumor necrosis factor agents in pregnant patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2013;11(3):286-292; quiz e224.
Gul A. Behcet’s disease as an autoinflammatory disorder. Curr Drug Targets Inflamm Allergy. 2005;4(1):81-83.
Mege JL, Dilsen N, Sanguedolce V, Gul A, Bongrand P, Roux H, et al. Overproduction of monocyte derived tumor necrosis factor alpha, interleukin (IL) 6, IL-8 and increased neutrophil superoxide generation in Behcet’s disease. A comparative study with familial Mediterranean fever and healthy subjects. J Rheumatol. 1993;20(9):1544- 1549.
Botsios C, Sfriso P, Furlan A, Punzi L, Dinarello CA. Resistant Behcet disease responsive to anakinra. Ann Intern Med. 2008;149(4):284-286.
Bilginer Y, Ayaz NA, Ozen S. Anti-IL-1 treatment for secondary amyloidosis in an adolescent with FMF and Behcet’s disease. Clin Rheumatol. 2010;29(2):209-210.
Emmi G, Silvestri E, Cameli AM, Bacherini D, Vannozzi L, Squatrito D, et al. Anakinra for resistant Behcet uveitis: why not? Clin Exp Rheumatol. 2013;31(3 Suppl 77):152-153.
Cantarini L, Vitale A, Scalini P, Dinarello CA, Rigante D, Franceschini R, et al. Anakinra treatment in drug-resistant Behcet’s disease: a case series. Clin Rheumatol. 2015;34(7):1293-1301.
Ugurlu S, Ucar D, Seyahi E, Hatemi G, Yurdakul S. Canakinumab in a patient with juvenile Behcet’s syndrome with refractory eye disease. Ann Rheum Dis. 2012;71(9):1589-1591.
Cantarini L, Vitale A, Borri M, Galeazzi M, Franceschini R. Successful use of canakinumab in a patient with resistant Behcet’s disease. Clin Exp Rheumatol. 2012;30(3 Suppl 72):S115.
Vitale A, Rigante D, Caso F, Brizi MG, Galeazzi M, Costa L, et al. Inhibition of interleukin-1 by canakinumab as a successful mono-drug strategy for the treatment of refractory Behcet’s disease: a case series. Dermatology. 2014;228(3):211-214.
.Fabiani C, Vitale A, Emmi G, Lopalco G, Vannozzi L, Guerriero S, et al. Interleukin (IL)-1 inhibition with anakinra and canakinumab in Behcet’s disease-related uveitis: a multicenter retrospective observational study. Clin Rheumatol. 2017;36(1):191- 197.
Gul A, Tugal-Tutkun I, Dinarello CA, Reznikov L, Esen BA, Mirza A, et al. Interleukin- 1beta-regulating antibody XOMA 052 (gevokizumab) in the treatment of acute exacerbations of resistant uveitis of Behcet’s disease: an open-label pilot study. Ann Rheum Dis. 2012;71(4):563-566.
Tugal-Tutkun IM, Kadayifcilar SM, Khairallah MM, Lee SCMP, Ozdal P, Ozyazgan Y, et al. Safety and Efficacy of Gevokizumab in Patients with Behcet’s Disease Uveitis: Results of an Exploratory Phase 2 Study. Ocul Immunol Inflamm. 2017;25(1):62- 70.
Kimura A, Kishimoto T. IL-6: regulator of Treg/Th17 balance. Eur J Immunol. 2010;40(7):1830-1835.
Hirano T, Ohguro N, Hohki S, Hagihara K, Shima Y, Narazaki M, et al. A case of Behcet’s disease treated with a humanized anti-interleukin-6 receptor antibody, tocilizumab. Mod Rheumatol. 2012;22(2):298-302.
Papo M, Bielefeld P, Vallet H, Seve P, Wechsler B, Cacoub P, et al. Tocilizumab in severe and refractory non-infectious uveitis. Clin Exp Rheumatol. 2014;32(4 Suppl 84):S75-79.
Calvo-Rio V, de la Hera D, Beltran-Catalan E, Blanco R, Hernandez M, Martinez- Costa L, et al. Tocilizumab in uveitis refractory to other biologic drugs: a study of 3 cases and a literature review. Clin Exp Rheumatol. 2014;32(4 Suppl 84):S54-57.
Deroux A, Chiquet C, Bouillet L. Tocilizumab in severe and refractory Behcet’s disease: Four cases and literature review. Semin Arthritis Rheum. 2016;45(6):733-737.
Santos-Gomez M, Calvo-Rio V, Blanco R, Beltran E, Mesquida M, Adan A, et al. The effect of biologic therapy different from infliximab or adalimumab in patients with refractory uveitis due to Behcet’s disease: results of a multicentre open-label study. Clin Exp Rheumatol. 2016;34 Suppl 102(6):34-40.
Eser Ozturk H, Oray M, Tugal-Tutkun I. Tocilizumab for the Treatment of Behcet Uveitis that Failed Interferon Alpha and Anti-Tumor Necrosis Factor-Alpha Therapy. Ocul Immunol Inflamm. 2017:1-10.
Alokaily F, Al Saati A, Jawad A. Successful treatment of Behcet’s uveitis with Tocilizumab. Saudi J Ophthalmol. 2017;31(1):42-44.
Deuter CM, Zierhut M, Igney-Oertel A, Xenitidis T, Feidt A, Sobolewska B, et al. Tocilizumab in Uveitic Macular Edema Refractory to Previous Immunomodulatory Treatment. Ocul Immunol Inflamm. 2016:1-6.
Adan A, Mesquida M, Llorenc V, Espinosa G, Molins B, Hernandez MV, et al. Tocilizumab treatment for refractory uveitis-related cystoid macular edema. Graefes Arch Clin Exp Ophthalmol. 2013;251(11):2627-2632.
Mesquida M, Molins B, Llorenc V, Sainz de la Maza M, Adan A. Long-term effects of tocilizumab therapy for refractory uveitis-related macular edema. Ophthalmology. 2014;121(12):2380-2386.
Cantarini L, Lopalco G, Vitale A, Coladonato L, Rigante D, Lucherini OM, et al. Paradoxical mucocutaneous flare in a case of Behcet’s disease treated with tocilizumab. Clin Rheumatol. 2015;34(6):1141-1143.
Diamantopoulos AP, Hatemi G. Lack of efficacy of tocilizumab in mucocutaneous Behcet’s syndrome: report of two cases. Rheumatology (Oxford). 2013;52(10):1923- 1924.
You C, Ma L, Lasave AF, Foster CS. Rituximab Induction and Maintenance Treatment in Patients with Scleritis and Granulomatosis with Polyangiitis (Wegener’s). Ocul Immunol Inflamm. 2017:1-8.
Cao JH, Oray M, Cocho L, Foster CS. Rituximab in the Treatment of Refractory Noninfectious Scleritis. Am J Ophthalmol. 2016;164:22-28.
Onal S, Kazokoglu H, Koc A, Yavuz S. Rituximab for remission induction in a patient with relapsing necrotizing scleritis associated with limited Wegener’s granulomatosis. Ocul Immunol Inflamm. 2008;16(5):230-232.
Miserocchi E, Modorati G, Berchicci L, Pontikaki I, Meroni P, Gerloni V. Longterm treatment with rituximab in severe juvenile idiopathic arthritis-associated uveitis. Br J Ophthalmol. 2016;100(6):782-786.
Heiligenhaus A, Miserocchi E, Heinz C, Gerloni V, Kotaniemi K. Treatment of severe uveitis associated with juvenile idiopathic arthritis with anti-CD20 monoclonal antibody (rituximab). Rheumatology (Oxford). 2011;50(8):1390-1394.
Lasave AF, You C, Ma L, Abusamra K, Lamba N, Valdes Navarro M, et al. Long- Term Outcomes of Rituximab Therapy in Patients with Noninfectious Posterior Uveitis Refractory to Conventional Immunosuppressive Therapy. Retina. 2017.
Davatchi F, Shams H, Rezaipoor M, Sadeghi-Abdollahi B, Shahram F, Nadji A, et al. Rituximab in intractable ocular lesions of Behcet’s disease; randomized single-blind control study (pilot study). Int J Rheum Dis. 2010;13(3):246-252.
Sadreddini S, Noshad H, Molaeefard M, Noshad R. Treatment of retinal vasculitis in Behcet’s disease with rituximab. Mod Rheumatol. 2008;18(3):306-308.

APA	ESER ÖZTÜRK H, Tugal-Tutkun I (2018). Behçet Hastalığına Bağlı Üveitin Tedavisinde Biyolojik Ajanların Kullanımı. , 358 - 365.
Chicago	ESER ÖZTÜRK HİLAL,Tugal-Tutkun Ilknur Behçet Hastalığına Bağlı Üveitin Tedavisinde Biyolojik Ajanların Kullanımı. (2018): 358 - 365.
MLA	ESER ÖZTÜRK HİLAL,Tugal-Tutkun Ilknur Behçet Hastalığına Bağlı Üveitin Tedavisinde Biyolojik Ajanların Kullanımı. , 2018, ss.358 - 365.
AMA	ESER ÖZTÜRK H,Tugal-Tutkun I Behçet Hastalığına Bağlı Üveitin Tedavisinde Biyolojik Ajanların Kullanımı. . 2018; 358 - 365.
Vancouver	ESER ÖZTÜRK H,Tugal-Tutkun I Behçet Hastalığına Bağlı Üveitin Tedavisinde Biyolojik Ajanların Kullanımı. . 2018; 358 - 365.
IEEE	ESER ÖZTÜRK H,Tugal-Tutkun I "Behçet Hastalığına Bağlı Üveitin Tedavisinde Biyolojik Ajanların Kullanımı." , ss.358 - 365, 2018.
ISNAD	ESER ÖZTÜRK, HİLAL - Tugal-Tutkun, Ilknur. "Behçet Hastalığına Bağlı Üveitin Tedavisinde Biyolojik Ajanların Kullanımı". (2018), 358-365.

APA	ESER ÖZTÜRK H, Tugal-Tutkun I (2018). Behçet Hastalığına Bağlı Üveitin Tedavisinde Biyolojik Ajanların Kullanımı. Güncel Retina Dergisi, 2(4), 358 - 365.
Chicago	ESER ÖZTÜRK HİLAL,Tugal-Tutkun Ilknur Behçet Hastalığına Bağlı Üveitin Tedavisinde Biyolojik Ajanların Kullanımı. Güncel Retina Dergisi 2, no.4 (2018): 358 - 365.
MLA	ESER ÖZTÜRK HİLAL,Tugal-Tutkun Ilknur Behçet Hastalığına Bağlı Üveitin Tedavisinde Biyolojik Ajanların Kullanımı. Güncel Retina Dergisi, vol.2, no.4, 2018, ss.358 - 365.
AMA	ESER ÖZTÜRK H,Tugal-Tutkun I Behçet Hastalığına Bağlı Üveitin Tedavisinde Biyolojik Ajanların Kullanımı. Güncel Retina Dergisi. 2018; 2(4): 358 - 365.
Vancouver	ESER ÖZTÜRK H,Tugal-Tutkun I Behçet Hastalığına Bağlı Üveitin Tedavisinde Biyolojik Ajanların Kullanımı. Güncel Retina Dergisi. 2018; 2(4): 358 - 365.
IEEE	ESER ÖZTÜRK H,Tugal-Tutkun I "Behçet Hastalığına Bağlı Üveitin Tedavisinde Biyolojik Ajanların Kullanımı." Güncel Retina Dergisi, 2, ss.358 - 365, 2018.
ISNAD	ESER ÖZTÜRK, HİLAL - Tugal-Tutkun, Ilknur. "Behçet Hastalığına Bağlı Üveitin Tedavisinde Biyolojik Ajanların Kullanımı". Güncel Retina Dergisi 2/4 (2018), 358-365.